Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
In the last three months, 6 analysts have published ratings on IDEAYA Biosciences (NASDAQ:IDYA), offering a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 3 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 2 | 0 | 0 | 0 |
2M Ago | 2 | 1 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for IDEAYA Biosciences, revealing an average target of $52.33, a high estimate of $57.00, and a low estimate of $43.00. This upward trend is evident, with the current average reflecting a 29.53% increase from the previous average price target of $40.40.
A comprehensive examination of how financial experts perceive IDEAYA Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Justin Zelin | BTIG | Announces | Buy | $55.00 | - |
Anupam Rama | JP Morgan | Raises | Overweight | $57.00 | $51.00 |
Gregory Renza | RBC Capital | Raises | Outperform | $53.00 | $43.00 |
Corinne Jenkins | Goldman Sachs | Raises | Buy | $53.00 | $36.00 |
Corinne Jenkins | Goldman Sachs | Raises | Buy | $53.00 | $36.00 |
Gregory Renza | RBC Capital | Raises | Outperform | $43.00 | $36.00 |
For valuable insights into IDEAYA Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on IDEAYA Biosciences analyst ratings.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: IDEAYA Biosciences's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -2.49%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IDEAYA Biosciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -865.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): IDEAYA Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.01% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): IDEAYA Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.74%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: IDEAYA Biosciences's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: IDYA